Document Detail

Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
MedLine Citation:
PMID:  20580567     Owner:  NLM     Status:  In-Data-Review    
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders that are preferentially diagnosed in the elderly. Aberrant expression of the adhesion receptor CD44 correlates with poor prognosis in various neoplasms. To evaluate the prognostic impact of CD44 in MDS serum levels of soluble CD44 standard (solCD44s) were measured in 130 MDS patients (median age 68 years) using an enzyme-linked immunosorbent assay (ELISA). solCD44s levels were significantly elevated in MDS patients as compared to those of healthy donors (p<0.001) and were found to correlate with distinct FAB and WHO subtypes. The highest levels of solCD44s were found in patients with CMML, in RAEB and in patients with MDS transformed into secondary acute myeloid leukaemia (AML). In univariate analysis elevated levels of solCD44s (cut-off level>688.5ng/ml) correlated significantly with shorter overall survival in MDS patients (12 versus 39 months; p<0.001). In multivariate analysis solCD44s displayed prognostic significance independent of the International Prognosis Scoring System (IPSS). To test for refined prognostication, IPSS risk groups were split into two separate categories based on the solCD44s levels. Using this approach, MDS patients with a shorter survival were identified both in the IPSS low-risk (p=0.037) and in the IPSS intermediate-1-risk group (p=0.015). The CD44s-adjusted IPSS defines a cohort of MDS patients with unfavorable prognosis, which might be helpful in risk stratification and in therapeutic algorithms.
J Loeffler-Ragg; U Germing; W R Sperr; H Herrmann; H Zwierzina; P Valent; H Ulmer; R Stauder
Related Documents :
12681367 - Clinical relevance of vegf receptors 1 and 2 in patients with chronic myelogenous leuke...
9368477 - Prognostic significance of dysplastic features of hematopoiesis in patients with de nov...
2914287 - Phase ii study of low-dose continuous infusion homoharringtonine in refractory acute my...
579337 - Serum glycylproline p-nitroanilidase activity in blood cancers.
23807827 - Visual field loss in schizophrenia: evaluation of magnocellular pathway dysfunction in ...
21897897 - Hyperparathyroidism revisited - old wine in new bottles!
Publication Detail:
Type:  Journal Article     Date:  2010-06-26
Journal Detail:
Title:  Critical reviews in oncology/hematology     Volume:  78     ISSN:  1879-0461     ISO Abbreviation:  Crit. Rev. Oncol. Hematol.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8916049     Medline TA:  Crit Rev Oncol Hematol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  150-61     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence -...
Next Document:  IFN-gamma enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more ef...